Filtered By:
Management: Profits and Losses
This page shows you your search results in order of relevance. This is page number 5.
Order by Relevance | Date
Total 84 results found since Jan 2013.
Penumbra shares rise on Q1 beat, growing sales
Shares in Penumbra (NYSE:PEN) rose today after the medical device maker topped expectations on Wall Street with its first quarter 2018 earnings results.
The Alameda, Calif.-based company posted profits of $5.5 million, or 15¢ per share, on sales of $102.7 million for the three months ended March 31, seeing a swing from the red on the bottom line while sales grew 40.3% compared with the same period during the previous year.
Earnings per share were well ahead of the 2¢ loss-per-share expectations on Wall Street, where analysts expected to see sales of $91.7 million, which the company also topped.
Penumbra lifted its sales...
Source: Mass Device - May 9, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Wall Street Beat Penumbra Inc. Source Type: news
Corindus Shares rise on Q3 EPS beat
Shares in Corindus Vascular Robotics (OTC:CVRS) have risen over 10% today after the robotic surgical platform maker beat loss-per-share expectations on Wall Street with its third quarter earnings.
The Waltham, Mass.-based company posted losses of approximately $7.6 million, or 4¢ per share, on sales of approximately $3 million for the three months ended September 30, seeing losses shrink 3.3% while sales grew 22% compared with the same period during the previous year.
Losses per share were just ahead of the 5¢ consensus on Wall Street, where analysts expected to see sales of $3.2 million, which the company narrowly miss...
Source: Mass Device - November 7, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Featured MassDevice Earnings Roundup Wall Street Beat Corindus Vascular Robotics Source Type: news
Corindus touts first-in-human coronary telerobotics study with CorPath system
Corindus Vascular Robotics (OTC:CVRS) today touted that its CorPath robotic surgical platform was used in a first-in-human telerobotic intervention study in India.
The Waltham, Mass.-based company touted that the study was the world’s first percutaneous coronary intervention conducted from a remote location outside of a catheterization lab.
In the trial, five patients at India’s Apex Heart Institute underwent an elective PCI procedure from a distance of approximately 20 miles away, Corindus said.
The procedures were performed by Apex Heart Institute chair and chief interventional cardiologist Dr. Tejas Patel f...
Source: Mass Device - December 6, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Clinical Trials Featured Robotics Corindus Vascular Robotics Source Type: news
A Quarter Century of APOE and Alzheimer’s Disease: Progress to Date and the Path Forward
Publication date: 6 March 2019Source: Neuron, Volume 101, Issue 5Author(s): Michaël E. Belloy, Valerio Napolioni, Michael D. GreiciusAlzheimer’s disease (AD) is considered a polygenic disorder. This view is clouded, however, by lingering uncertainty over how to treat the quasi “monogenic” role of apolipoprotein E (APOE). The APOE4 allele is not only the strongest genetic risk factor for AD, it also affects risk for cardiovascular disease, stroke, and other neurodegenerative disorders. This review, based mostly on data from human studies, ranges across a variety of APOE-related pathologies, touching on evolutionary g...
Source: Neuron - March 8, 2019 Category: Neuroscience Source Type: research
Corindus Vascular Robotics meets The Street with Q4 earnings
Corindus Vascular Robotics (OTC:CVRS) shares gained today after the robot-assisted surgery company reported fourth-quarter results that met the forecast on Wall Street.
Losses grew 3.1% for Waltham, Mass.-based Corindus posted to -$8.2 million, or -4¢ per share, on sales growth of 11.5% to $4.7 million for the three months ended Dec. 31, 2018, compared with the same period in 2017. Analysts were looking for LPS of -4¢.
Full-year losses were ip 25.0% to -$42.6 million, or -22¢ per share, on sales growth of 11.7% to $10.8 million compared with 2017.
“2019 is poised to be another significant year for Corindus. The succes...
Source: Mass Device - March 13, 2019 Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular MassDevice Earnings Roundup Robotics Wall Street Beat Corindus Vascular Robotics Source Type: news
Transcranial Direct Current Stimulation Use in Warfighting: Benefits, Risks, and Future Prospects
Conclusion
The aim of this paper was to examine whether military tDCS use can be efficacious and ethical in military settings. Our assessment is that tDCS offers a number of cognitive, motor, and perceptual enhancement opportunities which could provide value in military situations like training and operations. There is potential scope for use in a number of key areas that directly affect practical battlefield advantage and survivability, such as deceptive capabilities, risk-taking, threat detection, perception, and physiological improvement. Additionally, tDCS has the potential to improve command and control decision maki...
Source: Frontiers in Human Neuroscience - April 17, 2019 Category: Neuroscience Source Type: research
National Burden Estimates of healthy life lost in India, 2017: an analysis using direct mortality data and indirect disability data
Publication date: December 2019Source: The Lancet Global Health, Volume 7, Issue 12Author(s): Geetha R Menon, Lucky Singh, Palak Sharma, Priyanka Yadav, Shweta Sharma, Shrikant Kalaskar, Harpreet Singh, Srividya Adinarayanan, Vasna Joshua, Vaitheeswaran Kulothungan, Jeetendra Yadav, Leah K Watson, Shaza A Fadel, Wilson Suraweera, M Vishnu Vardhana Rao, R S Dhaliwal, Rehana Begum, Prabha Sati, Dean T Jamison, Prabhat JhaSummaryBackgroundMany countries, including India, seek locally constructed disease burden estimates comprising mortality and loss of health to aid priority setting for the prevention and treatment of disease...
Source: The Lancet Global Health - November 9, 2019 Category: International Medicine & Public Health Source Type: research
COVID-19 Business Updates Provide Some Clarity
The unknowns still outnumber the knowns, but recent business updates provide some clarity around how the medical device industry is fairing during the COVID-19 pandemic. First and foremost, it is clear that companies are hurting in the areas of elective procedures, which are being deferred. But there may be some silver linings hidden amongst the bad news.
Needham & Co. medtech analyst Mike Matson estimates that medical device sales across the industry will continue to drop by an average of 40% to 50% until the economy begins to reopen and hospitals start to resume elective procedures.
Matson's e...
Source: MDDI - April 10, 2020 Category: Medical Devices Authors: Amanda Pedersen Tags: COVID-19 Business Source Type: news
Johnson & Johnson Reports 2020 Third-Quarter Results
New Brunswick, N.J. (October 13, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2020. “Our third-quarter results reflect solid performance and positive trends across Johnson & Johnson, powered by better-than-expected procedure recovery in Medical Devices, growth in Consumer Health, and continued strength in Pharmaceuticals,” said Alex Gorsky, Chairman and Chief Executive Officer. “I am proud of the relentless passion and Credo-led commitment to patients and customers that our colleagues around the world continue to demonstrate as we boldly fight the COVID-19 pandemic. Our wo...
Source: Johnson and Johnson - October 13, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news
Rural U.S. Hospitals Are On Life Support As a Third Wave of COVID-19 Strikes
When COVID-19 hit the Southwest Georgia Regional Medical Center in Cuthbert, a small rural town in Randolph County, in late March, the facility—which includes a 25-bed hospital, an adjacent nursing home and a family-medicine clinic, was quickly overwhelmed. In just a matter of days, 45 of the 62 nursing home residents tested positive. Negative residents were isolated in the hospital while the severely ill patients from both the nursing home and the local community were transferred to other better-equipped facilities.
“We were trying to get the patients out as fast as possible,” says Steve Whatley, Southwe...
Source: TIME: Health - October 20, 2020 Category: Consumer Health News Authors: Emily Barone Tags: Uncategorized COVID-19 Source Type: news
Assessment of glucocorticoid tapering in large vessel and anti-neutrophil cytoplasmic antibody-associated vasculitides.
CONCLUSIONS: In one quarter of patients referred for LVV or AAV taking GC, tapering was slower than recommended. Promoting timely tapering may reduce GC toxicity.
PMID: 33338004 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - December 19, 2020 Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research
COVID-19 Exposed the Faults in America ’s Elder Care System. This Is Our Best Shot to Fix Them
For the American public, one of the first signs of the COVID-19 pandemic to come was a tragedy at a nursing home near Seattle. On Feb. 29, 2020, officials from the U.S. Centers for Disease Control and Prevention (CDC) and Washington State announced the U.S. had its first outbreak of the novel coronavirus. Three people in the area had tested positive the day before; two of them were associated with Life Care Center of Kirkland, and officials expected more to follow soon. When asked what steps the nursing home could take to control the spread, Dr. Jeff Duchin, health officer for Seattle and King County, said he was working w...
Source: TIME: Health - June 15, 2021 Category: Consumer Health News Authors: Abigail Abrams Tags: Uncategorized Aging COVID-19 feature franchise Magazine TIME for Health Source Type: news
Striving to Deliver Better Outcomes: Janssen to Showcase Commitment to Advancing Science for Genitourinary Cancers at AUA 2021
August 31, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple company-sponsored presentations in prostate and bladder cancers will be highlighted at the virtual 2021 American Urological Association Annual Meeting (AUA 2021), September 10-13. “Janssen maintains a strong commitment to advancing innovation and new therapeutic options for patients with genitourinary malignancies. As the treatment of genitourinary cancers becomes more complex, we continue to work with urologists and their teams to improve outcomes for patients across the continuum of disease,” sai...
Source: Johnson and Johnson - August 31, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
